{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:27:55Z","timestamp":1792114075792,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent therapeutic advances in the management of asthma have underscored the importance of eosinophilia and the role of pro-eosinophilic mediators such as IL-5 in asthma. Given that a subset of patients with COPD may display peripheral eosinophilia similar to what is observed in asthma, a number of recent studies have implied that eosinophilic COPD is a distinct entity. This review will seek to contrast the mechanisms of eosinophilia in asthma and COPD, the implications of eosinophilia for disease outcome, and review current data regarding the utility of peripheral blood eosinophilia in the management of COPD patients.<\/jats:p>","DOI":"10.1007\/s00408-021-00492-0","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:02:44Z","timestamp":1636106564000},"page":"589-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Eosinophilic Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"199","author":[{"given":"Jonathan C.","family":"Weissler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-459X","authenticated-orcid":false,"given":"Traci N.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"issue":"6","key":"492_CR1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pupt.2013.07.003","volume":"26","author":"SE Wenzel","year":"2013","unstructured":"Wenzel SE (2013) Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther 26(6):710\u2013715","journal-title":"Pulm Pharmacol Ther"},{"key":"492_CR2","unstructured":"Stevens AL (2010) Mechanical injury and inflammatory cytokines affect cartilage integrity and tissue homeostasis: a mass spectrometric analysis of proteins with relevance to arthritis. http:\/\/dspace.mit.edu\/%20handle\/1721.1\/37956. Accessed 22 Feb 2010"},{"key":"492_CR3","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0141PS","author":"SE Wenzel","year":"2016","unstructured":"Wenzel SE (2016) Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond. Am J Respir Cell Mol Biol. https:\/\/doi.org\/10.1165\/rcmb.2016-0141PS","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"492_CR4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11882-016-0662-1","volume":"16","author":"MP Giannetti","year":"2016","unstructured":"Giannetti MP, Cardet JC (2016) Interleukin-5 antagonists usher in a new generation of asthma therapy. Curr Allergy Asthma Rep 16(11):80","journal-title":"Curr Allergy Asthma Rep"},{"key":"492_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/COPD.S152291","volume":"13","author":"DP Tashkin","year":"2018","unstructured":"Tashkin DP, Wechsler ME (2018) Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 13:335\u2013349","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"492_CR6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/14656566.2015.1067682","volume":"16","author":"A D'Urzo","year":"2015","unstructured":"D\u2019Urzo A, Donohue JF, Kardos P, Miravitlles M, Price D (2015) A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 16(12):1845\u20131860","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"492_CR7","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al (2010) MEDI-563, a humanized anti\u2013IL-5 receptor \u03b1 mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125(6):1344\u201353.e2","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"492_CR8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","volume":"44","author":"H Neighbour","year":"2014","unstructured":"Neighbour H, Boulet LP, Lemiere C, Sehmi R, Leigh R, Sousa AR et al (2014) Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 44(4):508\u2013516","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"492_CR9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/00365513.2011.602422","volume":"71","author":"HP Sennels","year":"2011","unstructured":"Sennels HP, J\u00f8rgensen HL, Hansen A-LS, Goetze JP, Fahrenkrug J (2011) Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Investig 71(7):532\u2013541","journal-title":"Scand J Clin Lab Investig"},{"issue":"4","key":"492_CR10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.amjms.2017.03.020","volume":"354","author":"JC Weissler","year":"2017","unstructured":"Weissler JC (2017) Eosinophilic lung disease. Am J Med Sci 354(4):339\u2013349","journal-title":"Am J Med Sci"},{"issue":"6","key":"492_CR11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","volume":"3","author":"S Pascoe","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID (2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3(6):435\u2013442","journal-title":"Lancet Respir Med"},{"issue":"4","key":"492_CR12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","volume":"192","author":"SH Siddiqui","year":"2015","unstructured":"Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P et al (2015) Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192(4):523\u2013525","journal-title":"Am J Respir Crit Care Med"},{"issue":"9842","key":"492_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842):651\u2013659","journal-title":"Lancet"},{"issue":"8","key":"492_CR14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/02770903.2012.713428","volume":"49","author":"SL Spector","year":"2012","unstructured":"Spector SL, Tan RA (2012) Is a single blood eosinophil count a reliable marker for \u201cEosinophilic Asthma?\u201d J Asthma 49(8):807\u2013810","journal-title":"J Asthma"},{"issue":"1","key":"492_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaci.2010.04.011","volume":"126","author":"F Roufosse","year":"2010","unstructured":"Roufosse F, Weller PF (2010) Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 126(1):39\u201344","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"492_CR16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jaci.2015.04.005","volume":"136","author":"KG Blumenthal","year":"2015","unstructured":"Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP et al (2015) Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol 136(5):1288\u201394.e1","journal-title":"J Allergy Clin Immunol"},{"key":"492_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00427-2018","author":"T Southworth","year":"2018","unstructured":"Southworth T, Beech G, Foden P, Kolsum U, Singh D (2018) The reproducibility of COPD blood eosinophil counts. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00427-2018","journal-title":"Eur Respir J"},{"issue":"1","key":"492_CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ (2016) Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 138(1):16\u201327","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"492_CR19","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/thoraxjnl-2014-206736","volume":"70","author":"RY Kim","year":"2015","unstructured":"Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM (2015) Inflammasomes in COPD and neutrophilic asthma. Thorax 70(12):1199","journal-title":"Thorax"},{"issue":"1","key":"492_CR20","doi-asserted-by":"crossref","first-page":"e0145961","DOI":"10.1371\/journal.pone.0145961","volume":"11","author":"KC De Grove","year":"2016","unstructured":"De Grove KC, Provoost S, Verhamme FM, Bracke KR, Joos GF, Maes T et al (2016) Characterization and quantification of innate lymphoid cell subsets in human lung. PLoS ONE 11(1):e0145961","journal-title":"PLoS ONE"},{"issue":"9","key":"492_CR21","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","volume":"123","author":"DE Byers","year":"2013","unstructured":"Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X et al (2013) Long-term IL-33\u2013producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Investig 123(9):3967\u20133982","journal-title":"J Clin Investig"},{"issue":"7","key":"492_CR22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/thorax.57.7.590","volume":"57","author":"SL Traves","year":"2002","unstructured":"Traves SL, Culpitt SV, Russell REK, Barnes PJ, Donnelly LE (2002) Increased levels of the chemokines GRO\u03b1 and MCP-1 in sputum samples from patients with COPD. Thorax 57(7):590\u2013595","journal-title":"Thorax"},{"issue":"1","key":"492_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1378\/chest.07-0393","volume":"133","author":"C Costa","year":"2008","unstructured":"Costa C, Rufino R, Traves SL, Lapa e Silva JR, Barnes PJ, Donnelly LE (2008) CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 133(1):26\u201333","journal-title":"Chest"},{"key":"492_CR24","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.2147\/COPD.S170743","volume":"13","author":"M B\u00e9langer","year":"2018","unstructured":"B\u00e9langer M, Couillard S, Courteau J, Lariv\u00e9e P, Poder TG, Carrier N et al (2018) Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis 13:3045\u20133054","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"492_CR25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","volume":"150","author":"M Bafadhel","year":"2016","unstructured":"Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JEA, Morgan MD, Brightling CE et al (2016) Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 150(2):320\u2013328","journal-title":"Chest"},{"issue":"9","key":"492_CR26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","volume":"193","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG (2016) Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population study. Am J Respir Crit Care Med 193(9):965\u2013974","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"492_CR27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12931-018-0840-x","volume":"19","author":"SH Shin","year":"2018","unstructured":"Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH et al (2018) Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res 19(1):134","journal-title":"Respir Res"},{"issue":"12","key":"492_CR28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","volume":"5","author":"AT Hastie","year":"2017","unstructured":"Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S et al (2017) Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med 5(12):956\u2013967","journal-title":"Lancet Respir Med"},{"key":"492_CR29","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/COPD.S129787","volume":"12","author":"M Zysman","year":"2017","unstructured":"Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I et al (2017) Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chronic Obstruct Pulm Dis 12:1819\u20131824","journal-title":"Int J Chronic Obstruct Pulm Dis"},{"issue":"3","key":"492_CR30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.2010.135574","volume":"67","author":"HL Petsky","year":"2012","unstructured":"Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA et al (2012) A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 67(3):199\u2013208","journal-title":"Thorax"},{"issue":"1","key":"492_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","volume":"113","author":"TN Tran","year":"2014","unstructured":"Tran TN, Khatry DB, Ke X, Ward CK, Gossage D (2014) High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 113(1):19\u201324","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"492_CR32","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1365-2222.2010.03544.x","volume":"40","author":"A Vazquez-Tello","year":"2010","unstructured":"Vazquez-Tello A, Semlali A, Chakir J, Martin JG, Leung DY, Eidelman DH et al (2010) Induction of glucocorticoid receptor-\u03b2 expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin Exp Allergy 40(9):1312\u20131322","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"492_CR33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1164\/rccm.200507-1046OC","volume":"173","author":"E Goleva","year":"2006","unstructured":"Goleva E, Li L-B, Eves PT, Strand MJ, Martin RJ, Leung DYM (2006) Increased glucocorticoid receptor \u03b2 alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 173(6):607\u2013616","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"492_CR34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1378\/chest.129.1.151","volume":"129","author":"PJ Barnes","year":"2006","unstructured":"Barnes PJ (2006) Reduced histone deacetylase in COPD: clinical implications. Chest 129(1):151\u2013155","journal-title":"Chest"},{"issue":"3","key":"492_CR35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","volume":"131","author":"PJ Barnes","year":"2013","unstructured":"Barnes PJ (2013) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131(3):636\u2013645","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"492_CR36","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.bbadis.2017.05.003","volume":"1863","author":"M Ferraro","year":"2017","unstructured":"Ferraro M, Gjomarkaj M, Siena L, Di Vincenzo S, Pace E (2017) Formoterol and fluticasone propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial epithelial cells exposed to cigarette smoke. Biochim Biophys Acta 1863(7):1718\u20131727","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"492_CR37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA et al (2016) Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD. Thorax 71(2):118\u2013125","journal-title":"Thorax"},{"issue":"5","key":"492_CR38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","volume":"47","author":"NC Barnes","year":"2016","unstructured":"Barnes NC, Sharma R, Lettis S, Calverley PMA (2016) Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 47(5):1374","journal-title":"Eur Respir J"},{"issue":"18","key":"492_CR39","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC et al (2018) Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378(18):1671\u20131680","journal-title":"N Engl J Med"},{"issue":"23","key":"492_CR40","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT et al (2016) Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374(23):2222\u20132234","journal-title":"N Engl J Med"},{"issue":"1","key":"492_CR41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V et al (2020) Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res 21(1):3","journal-title":"Respir Res"},{"key":"492_CR42","doi-asserted-by":"crossref","first-page":"204062232110287","DOI":"10.1177\/20406223211028768","volume":"12","author":"T Liu","year":"2021","unstructured":"Liu T, Xiang ZJ, Hou XM, Chai JJ, Yang YL, Zhang XT (2021) Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 12:20406223211028770","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"492_CR43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","volume":"4","author":"I Pavord","year":"2016","unstructured":"Pavord I, Lettis S, Anzueto A, Barnes N (2016) Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 4(9):731\u2013741","journal-title":"Lancet Respir Med"},{"issue":"11","key":"492_CR44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","volume":"176","author":"P Flood-Page","year":"2007","unstructured":"Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L et al (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176(11):1062\u20131071","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"492_CR45","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS et al (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med 167(12):1655\u20131659","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"492_CR46","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198\u20131207","journal-title":"N Engl J Med"},{"issue":"7","key":"492_CR47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER et al (2016) Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4(7):549\u2013556","journal-title":"Lancet Respir Med"},{"issue":"5","key":"492_CR48","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R et al (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132(5):1086\u201396.e5","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"492_CR49","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N et al (2017) Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 377(17):1613\u20131629","journal-title":"N Engl J Med"},{"key":"492_CR50","unstructured":"Administration UFaD. sBLA 125526: Mepolizumab as add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) guided by blood eosinophil counts 2018"},{"issue":"11","key":"492_CR51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","volume":"2","author":"CE Brightling","year":"2014","unstructured":"Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK et al (2014) Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2(11):891\u2013901","journal-title":"Lancet Respir Med"},{"issue":"11","key":"492_CR52","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D et al (2019) Benralizumab for the prevention of COPD exacerbations. N Engl J Med 381(11):1023\u20131034","journal-title":"N Engl J Med"},{"key":"492_CR53","first-page":"CD013432","volume":"12","author":"T Donovan","year":"2020","unstructured":"Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I (2020) Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12:CD013432","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"492_CR54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/WOX.0b013e31821188e0","volume":"4","author":"EL Rael","year":"2011","unstructured":"Rael EL, Lockey RF (2011) Interleukin-13 signaling and its role in asthma. World Allergy Organ J 4(3):54","journal-title":"World Allergy Organ J"},{"key":"492_CR55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pharmthera.2016.10.016","volume":"169","author":"J Nixon","year":"2017","unstructured":"Nixon J, Newbold P, Mustelin T, Anderson GP, Kolbeck R (2017) Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther 169:57","journal-title":"Pharmacol Ther"},{"issue":"26","key":"492_CR56","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368(26):2455\u20132466","journal-title":"N Engl J Med"},{"issue":"10039","key":"492_CR57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388(10039):31\u201344","journal-title":"Lancet"},{"issue":"11","key":"492_CR58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard JP, Turnquist HR (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16(11):676\u2013689","journal-title":"Nat Rev Immunol"},{"key":"492_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00167-3","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM et al (2021) Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(21)00167-3","journal-title":"Lancet Respir Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00492-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-021-00492-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-021-00492-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T15:07:47Z","timestamp":1637939267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-021-00492-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s00408-021-00492-0","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}